HER3 Breast Text Module

CME

Elevating the Science of HER3-Targeted Therapy to Improve Outcomes in Breast Cancer

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: October 13, 2023

Expiration: October 12, 2024

Yuan Yuan
Yuan Yuan, MD, PhD

Activity

Progress
1
Course Completed

References

  1. Mishra R, Patel H, Alanazi S, et al. HER3 signaling and targeted therapy in cancer. Oncol Res. 2018;12:355.
  2. Xue C, Liang F, Mahmood R, et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res. 2006;66:1418-1426.
  3. Peddi PF, Hurvitz SA. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013;9:319-326.
  4. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617-628.
  5. Fam-trastuzumab deruxtecan-nxki [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; 2022.
  6. Sacituzumab govitecan-hziy [prescribing information]. Foster City, CA: Gilead Sciences;2023.
  7. Zhao P, Zhang Y, Li W. et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020;10:1589-1600.
  8. Krop IA, Masuda T, Mukohara T, et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I/II trial. J Clin Oncol. 2023;JCO2300882.
  9. Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29:2110-2120.
  10. Iwata H, Krop IE, Masuda T, et al. Phase 1/2 study of HER3-DXd in HER3-expressing Metastatic breast cancer: subgroup analysis by HER2 expression. Presented at: Japanese Society of Medical Oncology Annual Meeting; March 16-18, 2023. Abstract PS2-4.
  11. Hamilton EP, Dosunmu O, Shastry M, et al. A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). Presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 1004.
  12. Rugo HS, Crossno CL, Gesthalter YB, et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2–expressing metastatic breast cancer. JCO Oncology Practice. 2023;19:539-546.
  13. Oliveira M, Falato C, Cejalvo JM, et al. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Ann Oncol. 2023;34:670-680.
  14. Chic N, Luen SJ, Nucioro P, et al. Tumor cellularity and infiltrating lymphocytes as a survival surrogate in HER2-positive breast cancer. J Natl Cancer Inst. 2022;114:467-470.
  15. Pistilli B, Ibrahimi N, Lacroix-Triki M, et al. A phase 2 study of patritumab deruxtecan in patients with advanced breast cancer, with biomarker analysis to characterize response to therapy (ICARUS-BREAST01). Presented at: European Society for Medical Oncology Breast Cancer Annual Congress; May 11-13, 2023. Abstract 189O.